Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PHIO
PHIO logo

PHIO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Phio Pharmaceuticals Corp (PHIO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.110
1 Day change
-2.63%
52 Week Range
4.190
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

PHIO is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading in a weak technical setup, there are no recent news catalysts, no strong proprietary buy signals, and sentiment data is neutral. Based on the data provided, the best decision is to wait rather than buy now.

Technical Analysis

PHIO is in pre-market at 1.135, slightly down -0.44%. The trend is mixed to bearish: MACD histogram is positive and expanding, which is a short-term supportive sign, but the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the broader trend remains weak. RSI_6 at 67.245 is near overbought-neutral territory, so there is no clear fresh entry signal. Price is sitting right at resistance (R1 1.135) with pivot 1.097 and support at 1.059, which suggests limited upside room immediately and a risk of pullback if resistance holds.

Positive Catalysts

  • No news in the recent week. There are no significant hedge fund or insider buying trends, and no recent congress trading data. The only mild positive is that MACD is improving and currently positive, which can support a short-term bounce if momentum continues.

Neutral/Negative Catalysts

  • No recent news-driven catalysts. Hedge funds are neutral, insiders are neutral, and there is no recent congress trading activity. Similar candlestick pattern analysis suggests weak forward performance, with an estimated 50% chance of -0.66% next day, -0.5% next week, and -4.46% next month. The stock also lacks any AI Stock Picker or SwingMax signal today.

Financial Performance

No usable latest-quarter financial snapshot was provided due to a data error, so there is no reliable quarterly growth read available from the supplied information.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible Wall Street pros-and-cons shift to report.

Wall Street analysts forecast PHIO stock price to rise
1 Analyst Rating
Wall Street analysts forecast PHIO stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.140
sliders
Low
14
Averages
14
High
14
Current: 1.140
sliders
Low
14
Averages
14
High
14
H.C. Wainwright
H.C. Wainwright
initiated
$14
AI Analysis
2025-06-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$14
AI Analysis
2025-06-05
initiated
Reason
H.C. Wainwright assumed coverage of Phio Pharmaceuticals with a Buy rating and $14 price target. Phio's lead asset is PH-762 is an siRNA-based therapy formulated to safely inhibit PD-1 expression on T cells within the tumor microenvironment to drive anti-tumor activity, the analyst tells investors in a research note. The firm believes the company is "flying under the radar with investors" and has a bullish outlook for the stock.

People Also Watch